These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35464450)

  • 1. Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
    Leroux-Roels I; Waerlop G; Tourneur J; De Boever F; Maes C; Bruhwyler J; Guyon-Gellin D; Moris P; Del Campo J; Willems P; Leroux-Roels G; Le Vert A; Nicolas F
    Front Immunol; 2022; 13():852904. PubMed ID: 35464450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Leroux-Roels I; Willems P; Waerlop G; Janssens Y; Tourneur J; De Boever F; Bruhwyler J; Alhatemi A; Jacobs B; Nicolas F; Leroux-Roels G; Le Vert A
    Lancet Infect Dis; 2023 Dec; 23(12):1360-1369. PubMed ID: 37517422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
    Withanage K; De Coster I; Cools N; Viviani S; Tourneur J; Chevandier M; Lambiel M; Willems P; Le Vert A; Nicolas F; Van Damme P
    J Infect Dis; 2022 Aug; 226(1):119-127. PubMed ID: 34653245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza.
    Del Campo J; Bouley J; Chevandier M; Rousset C; Haller M; Indalecio A; Guyon-Gellin D; Le Vert A; Hill F; Djebali S; Leverrier Y; Marvel J; Combadière B; Nicolas F
    Front Immunol; 2021; 12():678483. PubMed ID: 34177921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.
    Evans TG; Bussey L; Eagling-Vose E; Rutkowski K; Ellis C; Argent C; Griffin P; Kim J; Thackwray S; Shakib S; Doughty J; Gillies J; Wu J; Druce J; Pryor M; Gilbert S
    Lancet Infect Dis; 2022 Jun; 22(6):857-866. PubMed ID: 35305317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study.
    Basu I; Agarwal M; Shah V; Shukla V; Naik S; Supe PD; Srivastava MK; Giriraja KV; Pinjar P; Mishra PK; Joshi S; Vijayakumar R; van de Witte S
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-10. PubMed ID: 33957854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
    Del Campo J; Pizzorno A; Djebali S; Bouley J; Haller M; Pérez-Vargas J; Lina B; Boivin G; Hamelin ME; Nicolas F; Le Vert A; Leverrier Y; Rosa-Calatrava M; Marvel J; Hill F
    NPJ Vaccines; 2019; 4():4. PubMed ID: 30701093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
    Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2012 Jun; 30(31):4655-60. PubMed ID: 22575166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial.
    Pleguezuelos O; Dille J; de Groen S; Oftung F; Niesters HGM; Islam MA; Næss LM; Hungnes O; Aldarij N; Idema DL; Perez AF; James E; Frijlink HW; Stoloff G; Groeneveld P; Hak E
    Ann Intern Med; 2020 Apr; 172(7):453-462. PubMed ID: 32150750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.
    Francis JN; Bunce CJ; Horlock C; Watson JM; Warrington SJ; Georges B; Brown CB
    Vaccine; 2015 Jan; 33(2):396-402. PubMed ID: 24928790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol.
    Swayze H; Allen J; Folegatti P; Yu LM; Gilbert S; Hill A; Ellis C; Butler CC
    F1000Res; 2019; 8():719. PubMed ID: 32089822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
    Antrobus RD; Lillie PJ; Berthoud TK; Spencer AJ; McLaren JE; Ladell K; Lambe T; Milicic A; Price DA; Hill AV; Gilbert SC
    PLoS One; 2012; 7(10):e48322. PubMed ID: 23118984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influvac Tetra: clinical experience on safety, efficacy, and immunogenicity.
    Colombo L; Hadigal S; Nauta J; Kondratenko A; Rogoll J; Van de Witte S
    Expert Rev Vaccines; 2024; 23(1):88-101. PubMed ID: 38088157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
    Pepin S; Nicolas JF; Szymanski H; Leroux-Roels I; Schaum T; Bonten M; Icardi G; Shrestha A; Tabar C;
    Hum Vaccin Immunother; 2021 Dec; 17(12):5475-5486. PubMed ID: 34714720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China.
    Zhu FC; Zhou W; Pan H; Lu L; Gerez L; Nauta J; Giezeman K; de Bruijn I
    Vaccine; 2008 Aug; 26(35):4579-84. PubMed ID: 18602729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
    Berthoud TK; Hamill M; Lillie PJ; Hwenda L; Collins KA; Ewer KJ; Milicic A; Poyntz HC; Lambe T; Fletcher HA; Hill AV; Gilbert SC
    Clin Infect Dis; 2011 Jan; 52(1):1-7. PubMed ID: 21148512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.